BioSpace News Archive

Certara, Inc., announced that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1, 2023.

CytoImmune Therapeutics today announced the appointment of Yulii Bogatyrenko as chief business officer.

Oragenics, Inc. today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301.

Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol “ZVRA” on the Nasdaq Global Select Market at market open today, March 1, 2023.

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”) is pleased to announce that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in Cowen’s 43rd Annual Health Care Conference, taking place on March 6 - 8, 2023 at the Boston Marriott Copley Place.

Atreca, Inc. today announced that John A. Orwin, President and Chief Executive Officer, will be participating in a panel discussion focused on novel oncology targets at Cowen’s 43rd Annual Health Care Conference on March 7, 2023.

aTyr Pharma, Inc. (Nasdaq: LIFE) today provided additional details regarding its plans to initiate a Phase 2 study of its lead therapeutic candidate, efzofitimod, in patients with systemic sclerosis (SSc, also known as scleroderma)-associated interstitial lung disease (ILD) following the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) announced earlier this year.

Global biotechnology leader CSL (ASX:CSL;USOTC:CSLLY), announced that The Lancet has published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE).

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB).

Insmed Incorporated today announced that management will present at the following investor conferences.